2. Academic Validation
  3. Discovery of a PCAF Bromodomain Chemical Probe

Discovery of a PCAF Bromodomain Chemical Probe

  • Angew Chem Int Ed Engl. 2017 Jan 16;56(3):827-831. doi: 10.1002/anie.201610816.
Moses Moustakim 1 2,  Peter G K Clark 3,  Laura Trulli 4,  Angel L Fuentes de Arriba 2,  Matthias T Ehebauer 5,  Apirat Chaikuad 6,  Emma J Murphy 5,  Jacqui Mendez-Johnson 7,  Danette Daniels 7,  Chun-Feng D Hou 8,  Yu-Hui Lin 8,  John R Walker 8,  Raymond Hui 8,  Hongbing Yang 9,  Lucy Dorrell 9,  Catherine M Rogers 1,  Octovia P Monteiro 1,  Oleg Fedorov 1,  Kilian V M Huber 1,  Stefan Knapp 6,  Jag Heer 10,  Darren J Dixon 2,  Paul E Brennan 1 5
Affiliations

Affiliations

  • 1 Structural Genomics Consortium & Target Discovery Institute, University of Oxford, NDM Research Building, Roosevelt Drive, Oxford, OX3 7DQ and OX3 7FZ, UK.
  • 2 Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford, OX1 3TA, UK.
  • 3 Department of Chemistry, Simon Fraser University, Burnaby, V5A 1S6, Canada.
  • 4 Dipartimento di Chimica, Università degli Studi di Roma "La Sapienza", Piazzale Aldo Moro 5, 00185, Roma, Italy.
  • 5 ARUK Oxford Drug Discovery Institute, University of Oxford, Oxford, OX3 7FZ, UK.
  • 6 Johann Wolfgang Goethe-University, Institute for Pharmaceutical Chemistry and Buchmann Institute for Life Sciences, 60438, Frankfurt am Main, Germany.
  • 7 Promega Corporation, 2800 Woods Hollow Road, Madison, WI, 153611, USA.
  • 8 Structural Genomics Consortium, MaRS South Tower, Suite 732, 101 College Street, Toronto, Ontario, M5G 1LZ, Canada.
  • 9 Nuffield Department of Medicine and Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, OX3 7FZ, UK.
  • 10 UCB Pharma Ltd, Slough, SL1 3WE, UK.
PMID: 27966810 DOI: 10.1002/anie.201610816
Abstract

The p300/CBP-associated factor (PCAF) and related GCN5 bromodomain-containing lysine acetyl transferases are members of subfamily I of the bromodomain phylogenetic tree. Iterative cycles of rational inhibitor design and biophysical characterization led to the discovery of the triazolopthalazine-based L-45 (dubbed L-Moses) as the first potent, selective, and cell-active PCAF bromodomain (Brd) inhibitor. Synthesis from readily available (1R,2S)-(-)-norephedrine furnished L-45 in enantiopure form. L-45 was shown to disrupt PCAF-Brd histone H3.3 interaction in cells using a nanoBRET assay, and a co-crystal structure of L-45 with the homologous Brd PfGCN5 from Plasmodium falciparum rationalizes the high selectivity for PCAF and GCN5 bromodomains. Compound L-45 shows no observable cytotoxicity in peripheral blood mononuclear cells (PBMC), good cell-permeability, and metabolic stability in human and mouse liver microsomes, supporting its potential for in vivo use.

Keywords

bromodomains; chemical probes; epigenetics; medicinal chemistry; structure-based design.

Figures
Products